Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
VEGF
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02873962IIPartially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT04919629IIRecurrent ovarian cancer with symptomatic ascites or pleural effusionRandomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
APL-2C3-targeted complement inhibitor APL-2Blocks the cleavage of C3Approved in Other Indications
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03697304IIAdvanced solid tumors with prior anti-PD-1/PD-L1 AbAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyCA, FL, IN, KY, OK, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BI 754111Blocks LAG-3 inhibition of T cellsClinical Trials
BI 836880anti-VEGF/ANG2 nanobody BI 836880VEGF and Angiopoietin 2 antagonistClinical Trials
Ezabenlimabanti-PD-1 monoclonal antibody BI 754091, BI 754091Blocks PD-L1/2 inhibition of T cellsClinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.